“…In some patients, by the end of the first week, the disease can have progression to pneumonia, respiratory failure, and death due to an extreme rise in inflammatory cytokines including IL-2, IL-7, IL-10, GCSF, IP10, MCP1, MIP1A, and TNF-α (Dong et al 2020;Mehta et al 2020, Ruan et al 2020Saghazadeh and Rezaei 2020;Yazdanpanah et al 2020;Zhou et al 2020a). Reported complications are lung impairment including severe respiratory failure and ARDS (Hussain et al 2020;Huang et al 2020;Robba et al 2020), shock (Alhazzani et al 2020;Li et al 2020b;Kamali Aghdam et al 2020), liver and kidney injury (Anders et al, 2020;Naicker et al, 2020;ten Cate 2020;Xu et al 2020), cardiac involvement (Chen et al 2020a;Shi et al, 2020;Liu et al, 2020), thromboembolic complications and coagulopathies (Matteo et al 2020;Orsi et al 2020;Simona et al 2020;Yang et al 2020), neurological manifestations, including acute transverse myelitis, acute encephalitis (Helms et al 2020;Jahanshahlu and Rezaei, 2020;Mao et al 2020;Saleki et al 2020), epileptic seizures, the Guillain-Barré syndrome (Carod-Artal 2020; Nalleballe et al 2020), neurological damage associated with mentioned coagulopathy, systemic and local thrombotic events which occur during this infection (Huang et al 2020) and ischemic or hemorrhagic stroke (Ashrafi et al 2020;Avula et al 2020;Oxley et al 2020). In this review, we discuss stroke as a presentation of COVID-19.…”